Solve GNE and Vecgen Awarded NIH Fast-Track STTR Grant to Develop a Diagnostic Predicting Immune Response to AAV Gene Therapy for GNE MyopathyÂ
Award structured across two phases with anticipated total value of approximately $2.5 million; firstphase funding of $333,689 is obligated and underway, with second-phase funding subject to NIH milestone review LOS ANGELES, California – Solve GNE, working in concert with Vecgen, Inc., announced today that a grant application the two organizations pursued together has been funded…